TY  - JOUR
AU  - Rosania, Rosa
AU  - Von Arnim, Ulrike
AU  - Link, Alexander
AU  - Rajilić-Stojanović, Mirjana
AU  - Franck, Caspar
AU  - Canbay, Ali
AU  - Malfertheiner, Peter
AU  - Venerito, Marino
PY  - 2018
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/4013
AB  - Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.
PB  - Medical Univ Press, Cluj-Napoca
T2  - Journal of Gastrointestinal and Liver Diseases
T1  - Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study
EP  - 125
IS  - 2
SP  - 119
VL  - 27
DO  - 10.15403/jgld.2014.1121.272.hpy
ER  - 

@article{
author = "Rosania, Rosa and Von Arnim, Ulrike and Link, Alexander and Rajilić-Stojanović, Mirjana and Franck, Caspar and Canbay, Ali and Malfertheiner, Peter and Venerito, Marino",
year = "2018",
abstract = "Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.",
publisher = "Medical Univ Press, Cluj-Napoca",
journal = "Journal of Gastrointestinal and Liver Diseases",
title = "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study",
pages = "125-119",
number = "2",
volume = "27",
doi = "10.15403/jgld.2014.1121.272.hpy"
}

Rosania, R., Von Arnim, U., Link, A., Rajilić-Stojanović, M., Franck, C., Canbay, A., Malfertheiner, P.,& Venerito, M.. (2018). Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases
Medical Univ Press, Cluj-Napoca., 27(2), 119-125.
https://doi.org/10.15403/jgld.2014.1121.272.hpy

Rosania R, Von Arnim U, Link A, Rajilić-Stojanović M, Franck C, Canbay A, Malfertheiner P, Venerito M. Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases. 2018;27(2):119-125.
doi:10.15403/jgld.2014.1121.272.hpy .

Rosania, Rosa, Von Arnim, Ulrike, Link, Alexander, Rajilić-Stojanović, Mirjana, Franck, Caspar, Canbay, Ali, Malfertheiner, Peter, Venerito, Marino, "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study" in Journal of Gastrointestinal and Liver Diseases, 27, no. 2 (2018):119-125,
https://doi.org/10.15403/jgld.2014.1121.272.hpy . .